Has the news around Vertex Pharmaceuticals effected PXS share price? from what I understand this treatment only expands their market by 750 patients (300k each). PXS could learn from the approach, get the product in the market with a smaller "tried and tested" subgroup, then grow.
As a bigger question, can PXS really survive (financially) until the completion of the trial 3, and FDA result?
It was always a gamble.
Vertex Pharmaceuticals & cash
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.49M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.7¢ | $7.351K | 408.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 850706 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 795780 | 4 |
View Market Depth
| Last trade - 16.10pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.7¢ |
Change
0.000 ( 5.56 %) |
||||
| Open | High | Low | Volume | ||
| 1.8¢ | 1.8¢ | 1.7¢ | 182209 | ||
| Last updated 14.45pm 15/05/2024 ? | |||||
| SNT (ASX) Chart |